Tirzepatide Research: SURPASS & SURMOUNT

Summary

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and for chronic weight management in several jurisdictions. The SURPASS and SURMOUNT programmes reported mean weight reductions of roughly 15–21% depending on dose and population. It has the most complete trial dataset of the current multi-receptor agents.

Last reviewed 2026-09-01

What it is

Tirzepatide is a 39–amino-acid synthetic peptide based on the native GIP sequence, modified with a C20 fatty diacid for albumin binding and once-weekly dosing, and engineered to activate both the GIP and GLP-1 receptors.

Developed by Eli Lilly and first approved for type 2 diabetes in 2022 (Mounjaro), followed by approval for chronic weight management (Zepbound) and later for obstructive sleep apnoea in adults with obesity in the US.

Synthetic; the backbone is GIP-derived rather than GLP-1-derived, which distinguishes it from earlier agents.

It demonstrated that GIP receptor activity added to GLP-1 activity produces greater weight and glycaemic effects than GLP-1 alone — reversing an earlier assumption that GIP antagonism would be the useful direction.

How it works

In plain terms

It acts on two gut-hormone systems at once. Together they reduce appetite, slow how quickly the stomach empties and improve how the body handles glucose more than either does alone.

Technical detail

Tirzepatide is an imbalanced agonist with greater potency at GIPR than GLP-1R relative to the native hormones. GLP-1R activation drives satiety signalling in the hypothalamus and area postrema, slows gastric emptying and enhances glucose-dependent insulin secretion while suppressing glucagon. GIPR activation adds insulinotropic effect, appears to improve adipose tissue insulin sensitivity and lipid buffering, and may reduce the nausea burden associated with GLP-1 activation through central GIPR signalling.

Pathways involved

GLP-1R: satiety, gastric emptying, insulin secretion
GIPR: insulinotropic effect, adipose insulin sensitivity
Combined hypothalamic and hindbrain appetite regulation
Albumin-bound weekly pharmacokinetics

Current research

Laboratory research

Receptor assays confirmed the imbalanced dual-agonist profile; adipocyte studies support a GIP-mediated role in lipid handling.

Animal research

Rodent studies showed additive weight and glycaemic effects over GLP-1 mono-agonism at matched exposure.

Human research

The SURPASS programme in type 2 diabetes reported HbA1c reductions of roughly 2.0–2.4 percentage points and superiority over semaglutide 1 mg in a head-to-head trial. SURMOUNT-1 reported mean weight reduction of about 20.9% at 72 weeks on 15 mg in adults with obesity without diabetes. SURMOUNT-OSA reported large reductions in apnoea–hypopnoea index. SUMMIT reported benefit in heart failure with preserved ejection fraction and obesity. Cardiovascular outcome data from SURPASS-CVOT has been reported as non-inferior to dulaglutide.

Ongoing research

Long-term outcome and comparative-effectiveness programmes continue across metabolic and cardiovascular indications.

What is being investigated

Glycaemic control in type 2 diabetes (approved indication)
Chronic weight management (approved indication)
Obstructive sleep apnoea in adults with obesity
Heart failure with preserved ejection fraction
Metabolic dysfunction-associated steatohepatitis

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Gastrointestinal adverse events are the most frequent reason for discontinuation in trials
Boxed warning for thyroid C-cell tumours based on rodent data; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2
Pancreatitis, gallbladder disease and, more rarely, severe gastroparesis have been reported
Lean mass loss accompanies fat loss; resistance training and protein intake are widely discussed as mitigations but trial evidence is limited
Weight regain after discontinuation was substantial in the SURMOUNT-4 withdrawal trial

Evidence ratings

Laboratory studies

Strong

Dual-receptor pharmacology well characterised.

Animal studies

Strong

Consistent additive effects over GLP-1 alone.

Human studies

Strong

Large Phase 3 programme across multiple indications.

Long-term safety

Moderate

Multi-year trial data available; decades-scale data is not.

Comparisons

Retatrutide vs Tirzepatide

Tirzepatide vs Semaglutide

References

[1]SURMOUNT-1 obesity trial — PubMed / NEJM, 2022
[2]SURPASS-2 head-to-head with semaglutide — PubMed / NEJM, 2021
[3]SURMOUNT-OSA sleep apnoea — PubMed / NEJM, 2024
[4]Registered tirzepatide trials — ClinicalTrials.gov, current
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is tirzepatide?+

A once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.

Is tirzepatide FDA approved?+

Yes — as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and, in the US, for obstructive sleep apnoea in adults with obesity.

How much weight loss did SURMOUNT-1 show?+

About 20.9% mean reduction at 72 weeks on the 15 mg dose, versus roughly 3% on placebo.

Is tirzepatide better than semaglutide?+

In SURPASS-2, tirzepatide produced greater HbA1c and weight reductions than semaglutide 1 mg. The SURMOUNT-5 head-to-head in obesity also favoured tirzepatide. Individual response varies.

Why does adding GIP help?+

GIP receptor activation adds insulinotropic effect and appears to improve how adipose tissue handles lipid, and may reduce nausea burden via central signalling.

What are the common side effects?+

Nausea, diarrhoea, vomiting, constipation and reduced appetite, generally dose-related and most pronounced during escalation.

Who should not take tirzepatide?+

It carries a boxed warning for thyroid C-cell tumours and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. This is a clinical decision, not a self-assessment.

Does weight return after stopping?+

SURMOUNT-4 showed substantial regain after withdrawal, consistent with obesity being a chronic condition rather than a time-limited one.

Is tirzepatide a peptide?+

Yes — a 39–amino-acid synthetic peptide with a fatty acid modification.

Continue your research

Retatrutide research

Semaglutide research

Incretin mechanisms of action